Publications for Dr. Michael Dellinger

Featured Publications

Impaired meningeal lymphatic vessel development worsens stroke outcome.

Yanev P, Poinsatte K, Hominick D, Khurana N, Zuurbier KR, Berndt M, Plautz EJ, Dellinger MT, Stowe AM 2019 Jan J. Cereb. Blood Flow Metab. 271678X18822921

cause generalized lymphatic anomaly.

Rodriguez-Laguna L, Agra N, Ibañez K, Oliva-Molina G, Gordo G, Khurana N, Hominick D, Beato M, Colmenero I, Herranz G, Torres Canizalez JM, Rodríguez Pena R, Vallespín E, Martín-Arenas R, Del Pozo Á, Villaverde C, Bustamante A, Ayuso C, Lapunzina P, Lopez-Gutierrez JC, Dellinger MT, Martinez-Glez V 2019 Feb J. Exp. Med. 2 216 407-418

VEGF-C promotes the development of lymphatics in bone and bone loss.

Hominick D, Silva A, Khurana N, Liu Y, Dechow PC, Feng JQ, Pytowski B, Rutkowski JM, Alitalo K, Dellinger MT 2018 Apr Elife 7

Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.

Regan E, Sibley RC, Cenik BK, Silva A, Girard L, Minna JD, Dellinger MT 2016 PLoS ONE 3 11 e0150963

Viewpoints on vessels and vanishing bones in Gorham-Stout disease.

Dellinger MT, Garg N, Olsen BR 2014 Jun Bone 63C 47-52

Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature.

Dellinger MT, Meadows SM, Wynne K, Cleaver O, Brekken RA 2013 PLoS ONE 9 8 e74686

Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice.

Dellinger M, Hunter R, Bernas M, Gale N, Yancopoulos G, Erickson R, Witte M 2008 Jul Dev. Biol. 2 319 309-20

Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia.

Dellinger MT, Hunter RJ, Bernas MJ, Witte MH, Erickson RP 2007 Aug Dev. Dyn. 8 236 2346-55

Cyclooxygenase-2 inhibition potentiates the efficacy of vascular endothelial growth factor blockade and promotes an immune stimulatory microenvironment in preclinical models of pancreatic cancer.

Zhang Y, Kirane A, Huang H, Sorrelle NB, Burrows FJ, Dellinger MT, Brekken RA 2018 Oct Mol. Cancer Res.

Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions.

Dellinger MT, Witte MH 2018 May Clin. Exp. Metastasis

Mir-126 is a conserved modulator of lymphatic development.

Kontarakis Z, Rossi A, Ramas S, Dellinger MT, Stainier DYR 2018 Mar Dev. Biol.

Hyperplasia, de novo lymphangiogenesis, and lymphatic regression in mice with tissue-specific, inducible overexpression of murine VEGF-D.

Lammoglia GM, Van Zandt CE, Galvan DX, Orozco JL, Dellinger MT, Rutkowski JM 2016 Jun Am. J. Physiol. Heart Circ. Physiol. ajpheart.00208.2016

Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis.

Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA 2015 Jul Cancer Res.

Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK.

Dbouk HA, Weil LM, Perera GK, Dellinger MT, Pearson G, Brekken RA, Cobb MH 2014 Nov Proc. Natl. Acad. Sci. U.S.A. 45 111 15999-6004

Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma.

Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, Dellinger MT, Castrillon DH, Brekken RA 2014 Feb Cancer Res. 4 74 1032-44

RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, Behrens C, Dellinger MT, Brekken RA, Wistuba II, Heguy A, Teruya-Feldstein J, Scaglioni PP 2013 Apr Cancer Discov 4 3 444-57

Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia.

Witte MH, Dellinger MT, Papendieck CM, Boccardo F 2012 Oct Clin. Exp. Metastasis 7 29 707-27

Stromal platelet-derived growth factor receptor a (PDGFRa) provides a therapeutic target independent of tumor cell PDGFRa expression in lung cancer xenografts.

Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N 2012 Nov Mol. Cancer Ther. 11 11 2473-82

Lymphangiogenesis and hemangiogenesis: potential targets for therapy.

Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JE 2011 May J Surg Oncol 6 103 489-500

The effects of targeting stromal and tumor cell platelet-derived growth factor receptor (PDGFR) in non-small cell lung cancer (NSCLC).

Gerber DE, Gupta P, Dellinger MT, Toombs J, Valencia I, Peyton M, Loizos N, Brekken RA 2011 May J. Clin. Oncol. 15_suppl 29 10533

Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax.

Kanady JD, Dellinger MT, Munger SJ, Witte MH, Simon AM 2011 Jun Dev. Biol. 2 354 253-66

Phosphorylation of Akt and ERK1/2 is required for VEGF-A/VEGFR2-induced proliferation and migration of lymphatic endothelium.

Dellinger MT, Brekken RA 2011 PLoS ONE 12 6 e28947

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA 2009 Jul Mol. Cancer Ther. 7 8 1761-71

Lymphedema-distichiasis syndrome without FOXC2 mutation: evidence for chromosome 16 duplication upstream of FOXC2.

Witte MH, Erickson RP, Khalil M, Dellinger M, Bernas M, Grogan T, Nitta H, Feng J, Duggan D, Witte CL 2009 Dec Lymphology 4 42 152-60

Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review.

Dellinger MT, Thome K, Bernas MJ, Erickson RP, Witte MH 2008 Sep Lymphology 3 41 98-102